SCHEMBL7559332

SCHEMBL7559332

O=C1OCOC1c1ccccc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 1/20 0.41
ALDH1A1 P00352 4/20 0.41
CA2 P00918 1/20 0.41
RAB9A P51151 1/20 0.39
SLC6A3 Q01959 1/20 0.39
KDM4E B2RXH2 4/20 0.38
MAPT P10636 3/20 0.38
POLB P06746 1/20 0.38
KMT2A Q03164 3/20 0.37
CYP19A1 P11511 3/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
GAA P10253 2/20 0.36
MEN1 O00255 2/20 0.36
CYP2C19 P33261 1/20 0.36
LMNA P02545 2/20 0.35
MAPK1 P28482 2/20 0.35
TP53 P04637 1/20 0.34
CYP1A2 P05177 1/20 0.34
CYP3A4 P08684 1/20 0.34
HTR2B P41595 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29055433 1.00 TSHR (0.41) TSHRALDH1A1CA2RAB9ASLC6A3
SCHEMBL24882533 0.89
SCHEMBL24882534 0.86 HDAC4 (0.37) TSHRMAPTCYP19A1SMN1; SMN2GAA
SCHEMBL11804128 0.82 TSHR (0.40) TSHRALDH1A1CA2RAB9ASLC6A3
SCHEMBL13311339 0.77 SMN1; SMN2 (0.41) TSHRALDH1A1CA2RAB9ASLC6A3
SCHEMBL28546410 0.76 LMNA (0.43) ALDH1A1RAB9AMAPTKMT2ACYP19A1
SCHEMBL30151912 0.73 CYP19A1 (0.43) ALDH1A1CA2KDM4EKMT2ACYP19A1
SCHEMBL31650964 0.72 ALDH1A1 (0.56) TSHRALDH1A1CA2RAB9ASLC6A3
SCHEMBL9361337 0.72 ALDH1A1 (0.39) TSHRALDH1A1CA2RAB9ASLC6A3
SCHEMBL9303316 0.72 ALDH1A1 (0.43) TSHRALDH1A1CA2RAB9ASLC6A3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1127043-A1 STEREOSELECTIVE PROCESS FOR PREPARING (CYCLO)ALKYL PHENYLGLYCOLIC ACIDS Sepracor Inc. (US) 2001-08-29 EP claimed
US-6180823-B1 CONDENSING SUBSTITUTED ACETALDEHYDE WITH ENANTIOMER OF MANDELIC ACID TO PROVIDE 5-PHENYL-1,3-DIOXOLAN-4-ONE, CONDENSING WITH CYCLOHEXANONE, DEHYDRATING PRODUCT, HYDROLYZING, REDUCING TO ALPHA-CYCLOHEXYLPHENYLGLYCOLIC ACID SEPRACOR INC. 2001-01-30 US claimed
WO-2000027786-A1 STEREOSELECTIVE PROCESS FOR PREPARING (CYCLO)ALKYL PHENYLGLYCOLIC ACIDS SEPRACOR INC. (US) 2000-05-18 WO claimed
CN-116217909-A Polymerization method of 1, 3-dioxolan-4-one compounds 华东理工大学 2023-06-06 CN disclosed
EP-3494106-B1 PROCESSES FOR MAKING, AND METHODS OF USING, GLYCOPYRRONIUM COMPOUNDS JOURNEY MEDICAL CORP (US) 2022-07-20 EP disclosed
US-11352323-B2 Processes for making, and methods of using, glycopyrronium compounds JOURNEY MEDICAL CORPORATION (US) 2022-06-07 US disclosed
US-6376684-B1 CHEMICAL INTERMEDIATE FOR OXYBUTYNIN-TYPE COMPOUNDS SEPRACOR INC. 2002-04-23 US disclosed
US-6376684-B1 CHEMICAL INTERMEDIATE FOR OXYBUTYNIN-TYPE COMPOUNDS SEPRACOR INC. 2002-04-23 US disclosed
EP-1191930-A2 METHODS FOR TREATMENT OF ASTHMA USING S-OXYBUTYNIN Sepracor Inc. (US) 2002-04-03 EP disclosed
US-6294582-B1 THERAPY OF REVERSIBLE OBSTRUCTIVE PULMONARY DISEASE BY ADMINISTERING OPTICALLY PURE S-OXYBUTYNIN OR ITS SALT SEPRACOR INC. 2001-09-25 US disclosed
EP-1127043-A1 STEREOSELECTIVE PROCESS FOR PREPARING (CYCLO)ALKYL PHENYLGLYCOLIC ACIDS Sepracor Inc. (US) 2001-08-29 EP disclosed
EP-1127043-A1 STEREOSELECTIVE PROCESS FOR PREPARING (CYCLO)ALKYL PHENYLGLYCOLIC ACIDS Sepracor Inc. (US) 2001-08-29 EP disclosed
US-6180823-B1 CONDENSING SUBSTITUTED ACETALDEHYDE WITH ENANTIOMER OF MANDELIC ACID TO PROVIDE 5-PHENYL-1,3-DIOXOLAN-4-ONE, CONDENSING WITH CYCLOHEXANONE, DEHYDRATING PRODUCT, HYDROLYZING, REDUCING TO ALPHA-CYCLOHEXYLPHENYLGLYCOLIC ACID SEPRACOR INC. 2001-01-30 US disclosed
US-6180823-B1 CONDENSING SUBSTITUTED ACETALDEHYDE WITH ENANTIOMER OF MANDELIC ACID TO PROVIDE 5-PHENYL-1,3-DIOXOLAN-4-ONE, CONDENSING WITH CYCLOHEXANONE, DEHYDRATING PRODUCT, HYDROLYZING, REDUCING TO ALPHA-CYCLOHEXYLPHENYLGLYCOLIC ACID SEPRACOR INC. 2001-01-30 US disclosed
WO-2000076490-A2 METHODS AND COMPOSITIONS FOR TREATING URINARY FREQUENCY AND URGENCY USING OPTICALLY PURE (S)-OXYBUTYNIN SEPRACOR INC. (US) 2000-12-21 WO disclosed
WO-2000071108-A2 METHODS FOR TREATMENT OF ASTHMA USING S-OXYBUTYNIN SEPRACOR INC. (US) 2000-11-30 WO disclosed
WO-2000027786-A1 STEREOSELECTIVE PROCESS FOR PREPARING (CYCLO)ALKYL PHENYLGLYCOLIC ACIDS SEPRACOR INC. (US) 2000-05-18 WO disclosed
WO-2000027786-A1 STEREOSELECTIVE PROCESS FOR PREPARING (CYCLO)ALKYL PHENYLGLYCOLIC ACIDS SEPRACOR INC. (US) 2000-05-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11352323-B2 Processes for making, and methods of using, glycopyrronium compounds GYPA, TPO, CYP21A2 TSHR 68/4885ALDH1A1 2560/4885CA2 1487/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.